Microphthalmia, syndromic 12 (MCOPS12)

Microphthalmia, syndromic 12 (MCOPS12) is an ultra-rare and complex neurological disease. It is caused by a single-point missense mutation in the retinoic acid receptor beta (RARB) gene. The most common disease symptoms are microphthalmia, severe (progressive) movement disorders and intellectual disability.[1] Movement disorders may include spasticity, dystonia and chorea. In addition, malformations such as incomplete lung development (pulmonary hypoplasia), defects of the cerebellum (Chiari type I malformation), and a defect/hole in the diaphragm (diaphragmatic hernia) have been observed.[1][2]

Gene

The retinoic acid receptor beta (RARB) gene (Gene ID: 5915) is located on the short (p) arm of chromosome 3 (3p24.2). It consists of 13 exons, four promoter regions and has a size of 423 kb in humans. RARB encodes retinoic acid receptor beta (RAR-beta), which belongs to the retinoic acid receptor family together with the other sub-types RAR-alpha and RAR-gamma.[3] Several variations of the single point mutation have been identified, with mutation c.1159C>T (p.R387C) being most prominent (i.e. cytosine is replaced by thymine in nucleotide 1159 causing arginine (R) at amino acid position 387 to be replaced by cysteine (C) in RAR-beta).[2] The respective variant impacts the disease phenotype, thus leading to heterogenous characteristics of the disease depending on the variant of the mutation.[1]

RAR-beta is a nuclear receptor and transcription factor. Upon activation by retinoic acid (the biologically active form of vitamin A), it regulates the expression of a plethora of genes in the human body. It plays a pivotal role in the development of the embryonic digestive tract, eye, myogenesis, and brain (especially the striatum).[4] Furthermore, RAR-beta is a tumor suppressor and hence has been in the focus of cancer therapy for almost two decades.[5]

Research

Mutations in the RAR-beta protein lead to MCOPS12 with pleiotropic defects of an unknown cause. The mutations in RAR-beta most likely result in conformational changes of the receptor’s ligand binding domain, hence to altered ligand binding and transcriptional activity of the receptor. These could be loss of function, reduction in function, or gain of normal function.[2]

Movement disorders are typically explained by some dysfunction in the striatum, which forms a critical part of the motor control system in the brain. Information input comes from the hindbrain by dopaminergic neurons, which connect to medium spiny neurons (MSN) in the striatum. The striatum contains two distinct types of MSNs (D1R and D2R) that carry information to different brain regions.[4] Both D1R and D2R are dopamine receptors.

RAR-beta is a transcription factor and the D2R dopamine receptor is one of its targets. It is hypothesized that changes in RAR-beta transcriptional activity change MSN gene expression, protein composition, and metabolic activity thus leading to the observed neurological disorders.[4]

The RAinRARE consortium federates research teams from four academic institutions to establish disease models and determine the mechanism through which mutant forms of RAR-beta affect striatum functions. Ultimately, the consortium aims to develop therapeutic approaches for MCOPS12 and robust biomarkers for monitoring the efficiency of these approaches. The teams have obtained funding by the European Union via the E-Rare platform to support this research program.

Patient advocacy

Cure MCOPS12 is a non-profit organization which was established in 2020 in Austria.[6] Its mission is to raise awareness and fundraising to support scientific research and clinical development that will ultimately result in a cure. Amongst others, Cure MCOPS12 has funded a Natural History Study for MCOPS12 patients, which is scheduled to start in 2021.

References
  1. Srour M, Chitayat D, Caron V, Chassaing N, Bitoun P, et al. (October 2013). "Recessive and Dominant Mutations in Retinoic Acid Receptor Beta in Cases with Microphthalmia and Diaphragmatic Hernia". American Journal of Human Genetics. 93 (4): 765–772. doi:10.1016/j.ajhg.2013.08.014. PMC 3791254. PMID 24075189.
  2. Srour M, Caron V, Pearson T, Nielsen SB, Lévesque S, Delrue MA, et al. (April 2016). "Gain-of-Function Mutations in RARB Cause Intellectual Disability with Progressive Motor Impairment". Human Mutation. 37 (8): 786–793. doi:10.1002/humu.23004. PMID 27120018. S2CID 22476576.
  3. di Masi A, Leboffe L, De Marinis E, Pagano F, Cicconi L, Rochette-Egly C, Lo-Coco F, Ascenzi P, Nervi C (February 2015). "Retinoic acid receptors: From molecular mechanisms to cancer therapy". Molecular Aspects of Medicine. 41: 1–115. doi:10.1016/j.mam.2014.12.003. PMID 25543955.
  4. Niewiadomska-Cimicka A, Krzyżosiak A, Ye T, Podleśny-Drabiniok A, Dembélé D, Dollé P, Krężel W (July 2016). "Genome-wide Analysis of RARβ Transcriptional Targets in Mouse Striatum Links Retinoic Acid Signaling with Huntington's Disease and Other Neurodegenerative Disorders". Molecular Neurobiology. 54 (5): 3859–3878. doi:10.1007/s12035-016-0010-4. PMID 27405468. S2CID 3789489.
  5. Houle B, Rochette-Egly C, Bradley WE (February 1993). "Tumor-suppressive effect of the retinoic acid receptor beta in human epidermoid lung cancer cells". Proceedings of the National Academy of Sciences of the United States of America. 90 (3): 985–89. Bibcode:1993PNAS...90..985H. doi:10.1073/pnas.90.3.985. PMC 45795. PMID 8381540.
  6. "CURE MCOPS12". CURE MCOPS12. Retrieved 18 May 2021.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.